6 results
The main study objective is to measure residual beta cell mass, indicated by the pancreatic uptake of Ga-68-exendin using quantitative PET, in type 1 diabetes patients with stable near-normal and unstable glucose control, to improve understanding of…
The study objective is to measure beta cell mass and function in subjects with type 1 diabetes during and shortly after the honeymoon phase, to determine whether the change in metabolic control is mainly caused by a decrease in the total number of…
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.
Primary:To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatmentSecondary:To assess the efficacy (exacerbations), FEV1 3h post dose, asthma symptoms, safety and tolerability.
The study objective is to compare the pituitary uptake of 68Ga-NODAGA-exendin in patients with and without adequate response (based on HbA1c or weight loss or classification by the treating diabetologist) to GLP-1R agonist treatment, to increase…
The primairy objective of this study is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes after FMT. Within 1 month…